KR20040033376A - Cosmetics composition comprising sophorolipids - Google Patents
Cosmetics composition comprising sophorolipids Download PDFInfo
- Publication number
- KR20040033376A KR20040033376A KR1020020062439A KR20020062439A KR20040033376A KR 20040033376 A KR20040033376 A KR 20040033376A KR 1020020062439 A KR1020020062439 A KR 1020020062439A KR 20020062439 A KR20020062439 A KR 20020062439A KR 20040033376 A KR20040033376 A KR 20040033376A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- skin
- acne
- corynebacterium
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 239000002537 cosmetic Substances 0.000 title claims abstract description 30
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims abstract description 10
- 239000006071 cream Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000006210 lotion Substances 0.000 claims abstract description 6
- 150000002632 lipids Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 abstract description 18
- 239000003876 biosurfactant Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001954 sterilising effect Effects 0.000 abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 10
- 239000000839 emulsion Substances 0.000 abstract description 4
- 241000191940 Staphylococcus Species 0.000 abstract description 3
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 3
- 241000192041 Micrococcus Species 0.000 abstract description 2
- 241000186429 Propionibacterium Species 0.000 abstract description 2
- 230000000050 nutritive effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 28
- 206010000496 acne Diseases 0.000 description 20
- 208000002874 Acne Vulgaris Diseases 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 235000019645 odor Nutrition 0.000 description 12
- 241000186427 Cutibacterium acnes Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 210000002374 sebum Anatomy 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 244000005700 microbiome Species 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 210000004243 sweat Anatomy 0.000 description 6
- 208000035985 Body Odor Diseases 0.000 description 5
- 206010040904 Skin odour abnormal Diseases 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- -1 polyoxyethylene monolauryl ether Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZTOKUMPYMPKCFX-CZNUEWPDSA-N (E)-17-[(2R,3R,4S,5S,6R)-6-(acetyloxymethyl)-3-[(2S,3R,4S,5S,6R)-6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxyoctadec-9-enoic acid Chemical compound OC(=O)CCCCCCC/C=C/CCCCCCC(C)O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O1 ZTOKUMPYMPKCFX-CZNUEWPDSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000186245 Corynebacterium xerosis Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000294506 Polygonum punctatum Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000007956 bioemulsifier Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940024473 salicylic acid emollient and protective preparations Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
[산업상 이용 분야][Industrial use]
본 발명은 소포로리피드를 포함하는 화장료 조성물에 관한 것으로, 더욱 상세하게는 미생물로부터 생산된 생물계면활성제인 소포로리피드를 유효성분으로 포함하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition comprising vesicle lipids, and more particularly, to a cosmetic composition comprising vesicle lipids, which are biosurfactants produced from microorganisms, as an active ingredient.
[종래 기술][Prior art]
생물계면활성제란 생물 유래의 계면활성물질을 모두 포괄하는 용어이지만, 흔히 미생물에 의해 생산되는 계면활성제를 말하는 것이다. 합성계면활성제의 피부 및 인체 안정성과 생분해 등의 문제와 이의 사용량 증가로 인한 여러 가지 환경 오염 문제가 점차 확대되면서 생물계면활성제의 연구 및 응용가능성이 증대되고 있는 실정이다. 이는 생물계면활성제가 종래의 합성 계면활성제와 달리 높은 생분해성과 안정성을 가지고 있고, 또한 합성 계면활성제에서는 볼 수 없는 구조상의 특징으로 인해 새로운 계면화학적 기능과 성능을 나타낼 수 있기 때문이다.Biosurfactant is a term encompassing all surfactants derived from living organisms, but often refers to surfactants produced by microorganisms. As the problems such as skin and human stability and biodegradation of synthetic surfactants and various environmental pollution problems caused by the increased use thereof, research and application of biosurfactants are increasing. This is because biosurfactants have high biodegradability and stability, unlike conventional synthetic surfactants, and may exhibit new surface chemical function and performance due to structural features not found in synthetic surfactants.
현재 생물계면활성제를 실용화한 예로, 일본의 가오화장품 회사(KAO Corp.)의 경우 토룰롭시드속(Torulopsis sp.) 효모로부터 당지질계 계면활성제를 생산하여 생물유화제(Bioemulsifier) 및 피부보습제로서 화장품에 실용화하고 있고, 바실러스 폴리믹사(Bacillus polymyxa)라는 박테리아에 의해 생산되는 미생물 고분자(Biopolymer)도 화장품 및 샴푸의 유용성분으로 이용되고 있다고 보고되어 있다.As an example of the biosurfactant in practical use, Japanese Kao Corp. (KAO Corp.) produces glycolipid surfactants from Torulopsis sp. Yeast to produce cosmetics as bioemulsifiers and skin moisturizers. In practical use, it is reported that a microbial polymer produced by a bacterium called Bacillus polymyxa is also used as a useful ingredient in cosmetics and shampoos.
한편, 여드름이란 면포(comedone), 구진(papule), 농포(pustule), 낭종, 또는 결절 형성을 특징으로 하는 모낭피지선의 만성 염증성 질환을 일컫는다. 여드름의 발병원인은 아직도 명확히 규명되어 있지 못하며, 다만 유전적 요인과 환경적 요인을 배제한다면 다음의 세 가지의 중요한 원인이 여드름 발병에 직접적으로 관여한다는 것이 지금까지의 연구 보고를 통하여 정설로서 인정되고 있다. 첫째는 과잉으로 분비되는 피지로, 피지의 형성은 남성호르몬의 작용에 의하여 이루어지며, 이 남성 호르몬의 비정상적 증가 또는 이와 관련된 여러 기전을 통하여 피지선은 기능이 항진되고 그 결과 과잉의 피지를 생성하게 된다. 둘째는 모낭의 과각화로 인한 모공의 폐쇄를 들 수 있다. 생성된 피지는 피부 밖으로 원활하게 배출되어야 하지만, 모낭의 과각화로 인하여 모공이 막혀 피지의 원활한 배출이 억제되고 그 결과 모낭내에 피지가 정체되어 미세면포를 형성하게 된다. 세 번째는 여드름균(Propionibacterium acnes)의 존재 때문으로 이것은 여드름 병변 악화의 중요한 원인으로 설명된다. 피지선내에 여드름 균의 증식이 많아짐에 따라 여드름 균에 의해 피지를 구성하고 있는 트리글리세라이드(triglyceride)가 자유 지방산(free fatty acid)으로 전환되어서 자극원으로 작용하거나, 면포유발성(comedogenic) 물질로 작용하여 여드름 생성을 촉진시켜 준다. 또한 더욱 진행되어 염증반응까지 수반하게 된다. 따라서, 현재까지 여드름 완화를 목적으로 하는 평가도 상기와 같은 작용 기전을 이용하여 피지분비 조절, 과각화 억제, 및 여드름 균에 대한 살균력 등을 평가하는 방법을 이용하여 수행되고 있다.On the other hand, acne refers to chronic inflammatory diseases of the hair follicle sebaceous glands characterized by the formation of comedones, papules, pustules, cysts, or nodules. The causes of acne are still not clearly identified, except that genetic and environmental factors may be directly involved in acne outbreaks. have. The first is sebum that is excessively secreted. The formation of sebum is caused by the action of male hormones, and the abnormal increase of this testosterone or various mechanisms associated with it causes sebaceous glands to become hyperfunctional, resulting in excess sebum. . Second is the closure of pores due to hyperkeratosis. The produced sebum should be discharged smoothly out of the skin, but the pores are blocked due to the exaggeration of the hair follicles, thereby suppressing the smooth discharge of sebum, and as a result, sebum is stagnated in the hair follicles to form microsurfaces. Third, due to the presence of propionibacterium acnes , this is explained as an important cause of acne lesion deterioration. As acne bacteria proliferate in the sebaceous glands, triglycerides that make up sebum are converted into free fatty acids and act as irritants or acne-producing substances. To promote acne production. It also progresses further and involves inflammatory reactions. Therefore, until now, evaluation for the purpose of alleviating acne has been carried out using a method of evaluating sebum secretion control, hyperkeratosis, and bactericidal activity against acne bacteria using the above-described mechanism of action.
이러한 여드름을 치료하기 위하여 종래에는 살리실산이나 비타민 A 유도체인 레티노익산 제제를 사용하여 모공의 각질 제거를 통하여 피지 분비를 원활하게 함으로써 치료효과를 가지게 하려는 시도가 있었으며, 또는 벤조일 퍼옥사이드 제제를 사용하여 피부 각질 제거와 강력한 항균작용을 통해서 치료를 하고자 하는 시도가 있었다. 그러나, 상기 살리실산 제제의 경우 미비한 치료 효과 뿐만 아니라 피부 발적, 부종 또는 피부 기피증 등을 일으킬 수 있으며, 레티노익산 제제의 경우 과각화 억제를 통한 효과는 있으나 접촉성 피부염, 홍반, 피부 건조, 및 박리현상 등이 일어날 수 있고, 또한 벤조일 퍼옥사이드 제제의 경우 알레르기성 접촉 피부염 및 상처를 남기고 심한 홍반이 생기는 등의 여러 부작용이 보고되고 있다. 또한 비교적 최근에 소개된 아젤래익 에시드(Azelaci acid) 제제의 경우 약물 부작용은 감소되었지만 기존 치료제 제품에 비하여 탁월한 임상 효과는 보고되지 못하는 실정이다.In order to treat such acne in the past, attempts have been made to have a therapeutic effect by smoothing the secretion of sebum through exfoliation of pores using salicylic acid or vitamin A derivative retinoic acid preparations, or by using benzoyl peroxide preparations. Attempts have been made to cure through exfoliation and strong antimicrobial activity. However, the salicylic acid preparations may cause skin redness, swelling or skin respiratory disease as well as insignificant therapeutic effects. In the case of retinoic acid preparations, the effect of hyperkeratosis is suppressed, but contact dermatitis, erythema, dry skin, and exfoliation may occur. This can happen, and many side effects have also been reported for benzoyl peroxide preparations such as allergic contact dermatitis and scarring and severe erythema. In addition, the relatively recently introduced azelaci acid preparations have reduced drug side effects, but excellent clinical effects are not reported compared to conventional therapeutic products.
또한, 인체의 체취는 인체에서 분비된 에크린땀(eccrine sweat), 아포크린땀(apocrine sweat), 피지, 오염물을 미생물 등이 분해시킴으로서 발생하게 된다. 즉, 처음 분비된 에크린땀이나 아포크린땀은 무취이나 피부표피, 털, 땀구멍 등에 상재하는 여러 미생물, 특히 체취와 관련된 미생물들의 작용으로 불쾌감을 일으키는 액취, 족취, 두취 등의 체취를 유발하게 된다. 피부에는 수많은 상재균이 존재하는데, 대표적인 것으로는 포도상구균인 스타필로코커스(Staphylococcus), 구균인 마이크로코커스(Micrococcus), 코리네박테리움(Corynebacterium), 프로피오니박테리움(Propionibacterium) 등이 있으며, 특히 코리네박테리움이 코를 자극하는 불쾌취로 강한 냄새 소유자에서 많이 발견되는 것으로 알려져 있다. 또한, 체취는 미생물의 분포수와도 밀접한 관계가 있는데, 겨드랑이, 발, 머리의 경우 기타 부위보다 미생물이 많이 존재하며, 이는 미생물이 살 수 있는 환경, 즉 털의 유무, 적정온도, 습도 등이 조성되기 때문인 것으로 밝혀져 있다.In addition, the body odor is generated by microorganisms decomposing eccrine sweat (apoccrine sweat), apocrine sweat (apocrine sweat), sebum, contaminants secreted by the human body. That is, the first secreted eccrine sweat or apocrine sweat causes odors such as odors, foot odors, and head odors caused by the action of various microorganisms, especially those associated with body odor, which are odorless or skin epidermis, hair, and pores. There are numerous floras on the skin, including Staphylococcus , Staphylococcus, Micrococcus , Corynebacterium , and Propionibacterium . Corynebacterium is known to be found in many strong odor holders due to nasal irritability. In addition, body odor is closely related to the distribution of microorganisms, and in the case of armpits, feet, and hair, there are more microorganisms than other parts. It turns out that it is because it is formed.
이러한 인체 체취에 대처할 수 있는 방법 중 항균 작용에 의한 체취 억제 방법으로 여러 연구가 진행되었으며, 항균 물질로는 트리클로산, 트리클로카반 등의 합성 물질이 알려져 있다. 그러나, 이러한 합성 항균 물질은 항균 작용은 우수하나, 피부 부작용 등의 문제가 있는 것으로 알려져 있다.Various studies have been conducted as a method for suppressing the body odor by the antibacterial action among the methods that can cope with the human body odor, and synthetic materials such as triclosan and triclocarban are known as antibacterial substances. However, these synthetic antimicrobial agents are known to have excellent antibacterial effects, but have problems such as skin side effects.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여, 여드름 균에 대한 항균 효과가 우수한 화장료 조성물을 제공하는 것을 목적으로 한다.In order to solve the problems of the prior art as described above, an object of the present invention is to provide a cosmetic composition excellent in antibacterial effect against acne bacteria.
본 발명의 다른 목적은 액취균에 대한 항균 효과가 우수한 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition excellent in antimicrobial effect against liquid odor bacteria.
본 발명의 다른 목적은 피부 보습효과, 사용감촉 및 피부유연 효과가 우수한 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition excellent in skin moisturizing effect, feeling of use and skin softening effect.
상기 목적을 달성하기 위하여, 본 발명은 캔디다 봄비오콜라(Candida bombiocola)(ATCC 22214)로부터 생산된 소포로리피드를 유효성분으로 포함하는 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition comprising a sopolori lipid produced from Candida bombiocola (ATCC 22214) as an active ingredient.
이하에서 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자는 종래 기술의 문제점을 해결하기 위하여, 화장료 조성물의 유효성분으로 합성화학물질이 아닌 천연물인 캔디다 봄비오콜라로부터 생산된 생물계면활성제인 소포로리피드를 이용할 경우 통상의 처방 제품에 비해 피부보습 및 유연효과가 우수하고, 여드름 균에 대한 항균 효과 및 액취균에 대한 항균 효과도 매우 우수함을 확인하여 본 발명을 완성하게 되었다.In order to solve the problems of the prior art, the present inventors use skin bio-surfactant, a biosurfactant produced from Candida Bombbio Cola, which is not a synthetic chemical, as an active ingredient of a cosmetic composition. And excellent in the softening effect, confirming the antibacterial effect against acne bacteria and antibacterial effect against liquid odor bacteria was completed the present invention.
본 발명에서 사용되는 생물계면활성제 생산 미생물은 효모의 일종인 캔디다 봄비오콜라(Candida bombiocola)를 사용한다. 상기 캔디다 봄비오콜라가 당지질계 계면활성제인 소포로리피드를 생산한다는 사실은 알려져 있으나, 다른 효과에 대해서는 아직까지 미미한 실정이다. 따라서, 본 발명에서는 소포로리피드의 계면활성제 역할 이외에, 피부보습효과 뿐만 아니라 여드름 및 액취균에 대한 살균효과 등을 새로이 확인하였다.The biosurfactant producing microorganism used in the present invention uses Candida bombiocola , a kind of yeast. It is known that the candida bombio cola produces a lipophilic surfactant, a glycolipid-based surfactant, but other effects are still insignificant. Therefore, in the present invention, in addition to the role of the surfactant of the vesicle lipids, as well as the skin moisturizing effect and the bactericidal effect against acne and odor bacteria newly confirmed.
본 발명의 화장료 조성물에서 유효성분으로 사용되는 소포로리피드는 계대 배양된 종균을 고압 멸균된 발효기에 접종하고 배양한 후, 원심분리 및 추출을 통해 얻을 수 있다.Sophorolipide used as an active ingredient in the cosmetic composition of the present invention can be obtained by inoculating and incubating passaged spawn seed in a high-pressure sterilized fermentor, followed by centrifugation and extraction.
이러한 소포로리피드는 하기 화학식 1 또는 화학식 2로 표시되는 구조를 갖는 것이 바람직하다.Such phospholipids preferably have a structure represented by the following general formula (1) or (2).
[화학식 1][Formula 1]
[화학식 2][Formula 2]
상기 식에서, R1, R2, 및 R3는 각각 독립적으로 또는 동시에 수소, 또는 -COCH3이며, R4는 탄소수 1 내지 20의 직쇄 또는 가지달린 알킬기이다.Wherein R 1 , R 2 , and R 3 are each independently or simultaneously hydrogen, or —COCH 3 , and R 4 is a straight or branched alkyl group having 1 to 20 carbon atoms.
본 발명에서 유효성분으로 포함하는 소포로리티드의 함량은 0.01 내지 10 중량%로 사용하는 것이 바람직하다. 상기 소포로리피드의 함량이 0.01 중량% 미만이면 소포로리피드의 의한 효과인 피부보습효과, 사용감촉과 피부유연효과, 및 여드름균과 액취균에 대한 항균효과가 거의 나타나지 않으며, 10 중량%를 초과하면 상승효과가 없고 사용감과 피부 촉감을 떨어뜨리는 경향이 있다.In the present invention, it is preferable to use the content of the sorocoretides as an active ingredient in an amount of 0.01 to 10% by weight. When the content of the vesicle lipid is less than 0.01% by weight, the skin moisturizing effect, the feeling of use and the skin softening effect, the antibacterial effect of the acne bacteria and the liquid odor bacteria, which are the effect of the sorborelipid, are rarely exceeded and exceeded 10% by weight. This has no synergistic effect and tends to degrade the feel and feel of the skin.
본 발명의 소포로리피드를 유효성분으로 포함하는 화장료 조성물은 일반 피부화장료에 배합되는 임의의 성분들을 필요에 따라 적절히 배합하여 사용할 수 있다. 상기 임의의 성분으로는 유분, 정제수, 계면활성제, 보습제, 저급알코올, 증점제, 킬레이트제, 색소, 방부제, 자외선 차단제, 산화방지제, 염료, 향료 등이 있다. 본 발명의 화장료 조성물의 예를 들면 화장수, 영양유액, 크림 또는 팩의 형태로 제형화되는 것이 바람직하지만, 이에 한정되는 것은 아니며, 여러 가지 다른 제형으로도 응용이 가능하다.The cosmetic composition comprising the vesicle lipid of the present invention as an active ingredient may be used by appropriately blending any ingredients blended into general skin cosmetics as needed. The optional components include oils, purified water, surfactants, humectants, lower alcohols, thickeners, chelating agents, pigments, preservatives, sunscreens, antioxidants, dyes, fragrances and the like. For example, the cosmetic composition of the present invention is preferably formulated in the form of a lotion, nutrient, cream or pack, but is not limited thereto, and may be applied to various other formulations.
이하 본 발명을 하기 실시예 및 비교예를 참조로 하여 설명한다. 그러나, 이들 예는 본 발명을 예시하기 위한 것일 뿐, 본 발명이 이들에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to the following Examples and Comparative Examples. However, these examples are only for illustrating the present invention, and the present invention is not limited thereto.
[실시예]EXAMPLE
제조예 1Preparation Example 1
(소포로리피드의 생산)(Production of phospholipid)
균주는 캔디다 봄비오콜라(Candida bombiocola) ATCC 22214를 사용하였으며, 사용한 배지의 조성은 다음과 같다. Candida bombiocola ( Candyda bombiocola ) ATCC 22214 was used, the composition of the medium was as follows.
배지 조성: 효모 추출물 3.0 g, 비프 익스트랙트 10.0 g, 펩톤 10.0 g, 가용성 전분 1.0 g, 포도당 5.0 g, L-시스테인 하이드로클로라이드 0.5 g, 염화나트륨 5.0 g, 소듐아세테이트 3.0 g, 아가 0.75 g, pH 6.8Medium composition: 3.0 g yeast extract, 10.0 g beef extract, 10.0 g peptone, 1.0 g soluble starch, 5.0 g glucose, 0.5 g L-cysteine hydrochloride, 5.0 g sodium chloride, 3.0 g sodium acetate, 0.75 g agar, pH 6.8
48 시간 동안 100 ml 플라스크에서 계대 배양한 종균을 고압멸균한 2.5 L 발효기에 접종하여 7일 동안 배양하였다. 배양이 끝난 후, 소포로리피드를 원심분리와 에틸아세테이트를 이용한 추출로 분리하였다.The seedlings passaged in a 100 ml flask for 48 hours were inoculated in a autoclaved 2.5 L fermenter and incubated for 7 days. After the incubation, the phospholipids were separated by centrifugation and extraction with ethyl acetate.
(여드름 균에 대한 항균력 평가 실험)(Antibacterial activity evaluation experiment on acne bacteria)
상기 방법으로 얻어진 소포로리피드의 여드름균에 대한 항균력 실험은 10 ml의 비에취아이(BHI) 액체 배지에서 전 배양시킨 피.아크네스(Propionibacterium acnes)를 108cell/ml 농도가 되도록 접종하고 일정 농도의 소포로리피드를 가하여 혐기성 배양기에서 48 시간 동안 배양한 후 피.아크네스의 수를 측정하여 최소 억제 농도를 구하였다. 그 결과, 소포로리피드의 피.아크네스에 대한 최소 억제 농도 범위는 150 내지 200 ppm으로 평가되었다.Antimicrobial activity test against acne bacteria of Sopholori lipid obtained by the above method was inoculated to 10 8 cell / ml concentration of Propionibacterium acnes pre-incubated in 10 ml BHI liquid medium. After culturing for 48 hours in an anaerobic incubator with a concentration of phophorolipid, the minimum inhibitory concentration was determined by measuring the number of P. acnes. As a result, the minimum inhibitory concentration range for Sophylori lipids against P. acnes was evaluated to be 150 to 200 ppm.
(액취 균에 대한 항균력 평가 실험)(Antibacterial activity evaluation experiment against liquid odor bacteria)
액취균으로는 코리네박테리움 제로시스(Corynebacterium xerosis) ATCC 7711을 사용하였다. 소포로리피드의 코리네박테리움 제로시스에 대한 항균력 실험은 10 ml의 비에취아이(BHI) 액체 배지에서 전 배양시킨 뒤, 코리네박테리움 제로시스를 106cell/ml 농도가 되도록 접종하고 일정 농도의 소포로리피드를 가하여 호기성 배양기에서 48 시간 동안 배양한 후 코리네박테리움 제로시스의 수를 측정하여 최소 억제 농도를 구하였다. 그 결과, 소포로리피드의 코리네박테리움 제로시스에 대한 최소 억제 농도 범위는 500 ppm으로 평가되었다.Corynebacterium xerosis ATCC 7711 was used as the liquid odor bacteria. Antimicrobial activity of Corynebacterium zerosis of Sophorolipid was pre-incubated in 10 ml of BHI liquid medium, followed by inoculation of Corynebacterium zerosis to a concentration of 10 6 cells / ml After culturing for 48 hours in an aerobic incubator with a concentration of Sophorolipid, the minimum inhibitory concentration was determined by measuring the number of Corynebacterium zeroes. As a result, the minimum inhibitory concentration range of Sophorolipid against Corynebacterium zerosis was evaluated at 500 ppm.
실시예 1 내지 2 및 비교예 1Examples 1-2 and Comparative Example 1
하기 표 1과 같은 통상적인 화장수의 조성 및 제조예 1에서 제조한 생물계면활성제인 소포로리피드를 첨가한 조성으로 화장수를 제조하였다. 정제수에 글리세린, 프로필렌글리콜, 자외선차단제 및 소포로리피드를 가하여 실온에서 용해시켰다. 한편, 에탄올에 올레일알코올, 폴리옥시에틸렌솔비탄모노라우린산에스테르, 폴리옥시에틸렌모노라우릴에테르, 방부제 및 향료를 가하여 실온에서 용해시키고, 이를 전술한 정제수부에 가하여 가용화시켰다. 이후, 염료로 조색한 후 여과하여 제품화하였다.Toner was prepared in the composition of the conventional lotion as shown in Table 1 and the composition to which the biosurfactant phophorolipid prepared in Preparation Example 1 was added. Glycerin, propylene glycol, a sunscreen and phospholipid were added to the purified water and dissolved at room temperature. On the other hand, oleyl alcohol, polyoxyethylene sorbitan monolauric acid ester, polyoxyethylene monolauryl ether, a preservative, and a fragrance | flavor were added to ethanol, and it melt | dissolved at room temperature, and it was solubilized by adding to the above-mentioned purified water. Thereafter, the mixture was colorized and filtered to produce a product.
실시예 3 내지 4 및 비교예 2Examples 3 to 4 and Comparative Example 2
하기 표 2와 같은 통상적인 영양유액 조성 및 제조예 1에서 제조한 생물계면활성제인 소포로리피드를 첨가한 조성으로 영양유액을 제조하였다. 정제수에 프로필렌글리콜과 소포로리피드를 가하여 가열 혼합한 다음, 에탄올을 넣어 70 ℃로 승온시켰다. 미리 조제한 카르복시비닐폴리머 수용액과 알칼리를 나머지 다른 친유성 성분과 혼합 가열하여 70 ℃가 되도록 하였다. 이후, 유상 부분을 가열하여 균일하게 혼합한 후, 알칼리를 가해서 중화시키고 호모게나이저(homogenizer)에 의해 균일하게 유화시킨 다음 열교환기에 의해 30 ℃까지 냉각시켜 제조하였다.A nutritive emulsion was prepared by adding a conventional nutritional fluid composition as shown in Table 2 below, and adding phospholipid, which is a biosurfactant prepared in Preparation Example 1. Propylene glycol and phospholipid were added to purified water, and the mixture was heated and mixed. Then, ethanol was added thereto and the temperature was raised to 70 ° C. The previously prepared aqueous solution of carboxyvinyl polymer and alkali were mixed and heated with the other lipophilic components to 70 ° C. Thereafter, the oil phase part was heated and uniformly mixed, neutralized by addition of alkali, uniformly emulsified by a homogenizer, and cooled to 30 ° C. by a heat exchanger.
실시예 5 내지 6 및 비교예 3Examples 5-6 and Comparative Example 3
하기 표 3과 같은 통상적인 크림의 조성 및 제조예 1에서 제조한 생물계면활성제인 소포로리피드를 첨가한 조성으로 크림을 제조하였다. 정제수에 프로필렌글리콜과 소포로리피드를 가하여 혼합한 다음, 70 ℃로 승온시켰다. 나머지 성분들은 혼합하여 가열 용해시켜 70 ℃가 되도록 하고 이를 수상부에 가해서 예비 유화시키고 호모게나이저(homogenizer)로 균일하게 유화시킨 다음 열교환기에 의해 실온까지 냉각시켜 제조하였다.To prepare a cream with a composition of a conventional cream as shown in Table 3 and the composition added to the biosurfactant phophorolipid prepared in Preparation Example 1. Propylene glycol and phospholipid were added to the purified water, mixed, and then heated to 70 ° C. The remaining ingredients were mixed and dissolved by heating to 70 ° C., preliminarily emulsified in the aqueous phase, homogenized with a homogenizer and cooled to room temperature by a heat exchanger.
실시예 7 내지 8 및 비교예 4Examples 7 to 8 and Comparative Example 4
하기 표 4와 같은 통상적인 팩의 조성 및 제조예 1에서 제조한 생물계면활성제인 소포로리피드를 첨가한 조성으로 팩을 제조하였다. 정제수에 솔비트와 소포로리피드를 가하여 혼합하고 여기에 산화티탄과 카올린, 산화비닐수지에멀션을 첨가한 다음, 일부의 에탄올로 습윤시킨 폴리비닐알코올을 가하여 70 ℃로 가열 용해시켰다. 남은 알코올에 향료, 방부제를 가하여 혼합하고 최종적으로 올리브유를 첨가하여 냉각시켜 제품을 만들었다.To prepare a pack with the composition of the conventional pack as shown in Table 4 and the composition added to the biosurfactant phophorolipid prepared in Preparation Example 1. Solbite and sorbolipid were added to the purified water, mixed with titanium oxide, kaolin and an emulsion of vinyl oxide resin, and polyvinyl alcohol moistened with some ethanol was added thereto, followed by heating and dissolving at 70 ° C. Flavor and preservatives were added to the remaining alcohol and mixed, and finally, olive oil was added to cool the product.
실험예 1Experimental Example 1
(수분보유능 측정시험)(Moisture retention test)
소포로리피드의 수분 보유능을 알아보기 위하여, 손등 부위가 건조한 성인 남ㆍ여 20 명을 대상으로 1일 2회씩 총 3개월 동안 다음과 같은 실험을 수행하였다. 먼저 피시험자 손등의 4cm × 4cm 면적 부분에 각각 사용 전후의(1개월) 피부의 수분함량을 피부수분함량 측정장치(스킨 설피스 하이그로미터(Skin Surface Hygrometer), 모델명: SKICON-200, 일본 IBS사 제품)를 이용하여 측정하였고, 그 결과는 하기 표 5에 나타내었다. 여기서 사용된 수치의 단위는 ㎲이다.In order to determine the water retention ability of the vesicle lipids, the following experiment was conducted twice a day for 20 months on the male and female adults with dry hands. First, the skin moisture content measuring device (skin skin hygrometer), model name: SKICON-200, Japan IBS Product) and the results are shown in Table 5 below. The unit of measure used here is ㎲.
상기 표 5에서 알 수 있듯이, 건조한 피부에 대하여 본 발명의 실시예 1 내지 8의 화장료를 도포한 후에 수분 보유능이 증가되었다. 또한, 실시예 1 내지 8의 경우 비교예 1 내지 4의 화장료를 도포한 것에 비해 수분 보유능이 더욱 증가되어 피부보습 및 유연효과가 우수함을 알 수 있다.As can be seen in Table 5, after applying the cosmetic of Examples 1 to 8 of the present invention on dry skin, the water retention capacity was increased. In addition, in the case of Examples 1 to 8 it can be seen that the moisture retention ability is further increased compared to the cosmetics of Comparative Examples 1 to 4 it is excellent in the skin moisturizing and softening effect.
실험예 2Experimental Example 2
(피.아크네스에 대한 살균력 실험)(Sterilization test on P. acnes)
실시예 1 내지 8 및 비교예 1 내지 4에서 제조한 화장료 조성물의 피.아크네스에 대한 항균력을 평가하기 위하여, 멸균된 비에취아이(BHI) 액체 배지가 10 ml 담긴 시험관에 피.아크네스를 접종하여 2일간 혐기성 배양기에서 배양하고, 피.아크네스의 집락수(N1)를 측정하였으며, 실시예 및 비교예의 10% 화장료 수용액을 상기 시험관에 1 g을 첨가하여 1일간 혐기성 배양기에서 배양시킨 후 집락수(N2)를 측정하였다. 상기에 의하여 구하여진 집락수를 이용하여 피.아크네스에 대한 살균력을 평가하였다. 피.아크네스의 살균율은 90% 이상의 결과가 있어야 살균효과가있는 것으로 판단한다. 피.아크네스에 대한 살균력 실험결과는 하기 표 6에 나타내었다.In order to evaluate the antimicrobial activity of P. acnes of the cosmetic compositions prepared in Examples 1 to 8 and Comparative Examples 1 to 4, P. acne was added to a test tube containing 10 ml of sterile BHI liquid medium. Inoculated and incubated in an anaerobic incubator for 2 days, and the colony number (N1) of P. acnes was measured, and 1 g of 10% cosmetic solution of Examples and Comparative Examples was added to the test tube and then incubated in an anaerobic incubator for 1 day. Colony number N2 was measured. The bactericidal power against P. acnes was evaluated using the colony number obtained above. The bactericidal rate of P. acnes should be more than 90% in order to be effective. The bactericidal test results for P. acnes are shown in Table 6 below.
상기 표 6에서 보면, 실시예 1 내지 8의 경우 비교예 1 내지 4와 비교하여 피.아크네스에 대한 살균율이 월등히 우수함을 알 수 있다. 특히, 실시예 1 및 2의 경우 피.아크레스에 대한 살균율이 99.99 및 99.95%로 매우 우수하였다.In Table 6, it can be seen that in Examples 1 to 8, the sterilization rate for P. acnes was much better than that of Comparative Examples 1 to 4. In particular, in Examples 1 and 2, the sterilization rates for P. acres were 99.99 and 99.95%.
실험예 3Experimental Example 3
(코리네박테리움 제로시스에 대한 살균력 실험)(Sterilization test for Corynebacterium zerosis)
실시예 1 내지 8 및 비교예 1 내지 4에서 제조한 화장료 조성물의 코리네박테리움 제로시스에 대한 항균력을 평가하기 위하여, 트윈-80이 0.1% 첨가된 멸균된 비에치아이(BHI) 액체 배지가 10 ml 담긴 시험관에 코리네박테리움 제로시스를 접종하여 2일간 호기성 배양기에서 배양하고 코리네박테리움 제로시스의 집락수(N1)를 측정하였으며, 실시예 및 비교예의 화장료를 상기 시험관에 1 g을 첨가하여 1일간 혐기성 배양기에서 배양시킨 후 집락수(N2)를 측정하였다. 상기에 의하여 구하여진 집락수를 이용하여 코리네박테리움 제로시스에 대한 살균력을 평가하였다. 코리네박테리움 제로시스의 살균율은 90% 이상의 결과가 있어야 살균효과가 있는 것으로 판단한다. 코리네박테리움 제로시스에 대한 살균력 실험결과는 하기 표 7에 나타내었다.In order to evaluate the antimicrobial activity against Corynebacterium zerosis of the cosmetic compositions prepared in Examples 1 to 8 and Comparative Examples 1 to 4, sterilized BH liquid medium containing 0.1% of Tween-80 was added. Corynebacterium zerosis was inoculated into a test tube containing 10 ml, and cultured in an aerobic incubator for 2 days, and the colony count (N1) of Corynebacterium zerosis was measured, and 1 g of the cosmetics of Examples and Comparative Examples were added to the test tube. Colonies (N2) were measured after 1 day of incubation in an anaerobic incubator. The bactericidal activity against Corynebacterium zerosis was evaluated using the colony numbers obtained above. The sterilization rate of Corynebacterium zerosis should be more than 90% in order to be effective. Results of bactericidal power for Corynebacterium zerosis are shown in Table 7 below.
상기 표 7에서 보면, 실시예 1 내지 8의 경우 비교예 1 내지 4와 비교하여 코리네박테리움 제로시스에 대한 살균율이 월등히 우수함을 알 수 있다. 특히, 실시예 1의 경우 코리네박테리움 제로시스에 대한 살균율이 99로 매우 우수하였다.In Table 7, it can be seen that in Examples 1 to 8, compared to Comparative Examples 1 to 4, the sterilization rate for Corynebacterium zerosis is excellent. In particular, in Example 1, the sterilization rate against Corynebacterium zerosis was 99, which was very good.
이상에서 살펴본 바와 같이, 본 발명은 천연 미생물을 배양하여 생산된 소포로리피드를 생물계면활성제로 포함하여 여드름균과 액취균에 대한 살균효과, 피부보습효과, 및 사용감촉과 피부유연 효과가 매우 우수한 화장료 조성물을 제공할 수 있다.As described above, the present invention includes a microorganism produced by culturing natural microorganisms as a biosurfactant, the bactericidal effect, acne moisturizing effect on the acne and liquid odor bacteria, and the feeling of use and skin softness is very excellent Cosmetic compositions can be provided.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020062439A KR20040033376A (en) | 2002-10-14 | 2002-10-14 | Cosmetics composition comprising sophorolipids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020062439A KR20040033376A (en) | 2002-10-14 | 2002-10-14 | Cosmetics composition comprising sophorolipids |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20040033376A true KR20040033376A (en) | 2004-04-28 |
Family
ID=37332812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020062439A Ceased KR20040033376A (en) | 2002-10-14 | 2002-10-14 | Cosmetics composition comprising sophorolipids |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20040033376A (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011120776A1 (en) | 2010-03-31 | 2011-10-06 | Unilever Plc | Mild to the skin, foaming detergent composition |
DE102011090030A1 (en) | 2011-12-28 | 2013-07-04 | Evonik Industries Ag | Aqueous hair and skin cleansing compositions containing biosurfactants |
DE102013206314A1 (en) | 2013-04-10 | 2014-10-16 | Evonik Industries Ag | Cosmetic formulation containing copolymer as well as sulfosuccinate and / or biosurfactant |
EP3070155A1 (en) | 2015-03-18 | 2016-09-21 | Evonik Degussa GmbH | Composition comprising peptidase and biosurfactant |
WO2016207203A1 (en) | 2015-06-25 | 2016-12-29 | Basf Se | Additive for alkaline zinc plating |
EP3290501A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Detergent compositions containing alkoxylated fatty acid amides |
EP3290020A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Mild preparations containing alkoxylated fatty acid amides |
EP3290500A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Detergent composition and care composition containing polyoxyalkylene carboxylate |
WO2018101717A1 (en) * | 2016-11-29 | 2018-06-07 | 바이오인터체인지주식회사 | Composition containing sophorolipid as active ingredient for preventing hair loss or promoting hair growth |
WO2018145966A1 (en) | 2017-02-10 | 2018-08-16 | Evonik Degussa Gmbh | Oral care composition containing at least one biosurfactant and fluoride |
WO2018197623A1 (en) | 2017-04-27 | 2018-11-01 | Evonik Degussa Gmbh | Biodegradable cleaning composition |
KR20190023016A (en) * | 2017-08-25 | 2019-03-07 | 주식회사 더가든오브내추럴솔루션 | Anti acne cosmetic composition and preparation method of the same comprising the mixed extract of Sopholiance S, Withania Somnifera Root, Coriandrum Sativum and Propolis |
KR20190033962A (en) * | 2017-09-22 | 2019-04-01 | 주식회사 유나이티드엑티브 | Fermented emulsifier using microorganism and preparation thereof |
WO2019214968A1 (en) | 2018-05-11 | 2019-11-14 | Basf Se | Detergent composition comprising rhamnolipids and/or mannosylerythritol lipids |
KR20190141904A (en) * | 2018-06-15 | 2019-12-26 | 한국생명공학연구원 | Method for high production of sophorolipid using Candida bombicola LA-200 strain having sophorolipid production activity |
CN110831571A (en) * | 2017-05-07 | 2020-02-21 | 轨迹Ip有限责任公司 | Cosmetic composition for skin health and method of use |
US11591547B2 (en) | 2017-04-27 | 2023-02-28 | Evonik Operations Gmbh | Biodegradable cleaning composition |
EP4234671A1 (en) | 2022-02-24 | 2023-08-30 | Evonik Operations GmbH | Compositions containing biosurfactants and a lipase from stachybotrys chlorohalonata |
WO2023161179A1 (en) | 2022-02-24 | 2023-08-31 | Evonik Operations Gmbh | New composition containing liposomes and biosurfactants |
EP4269531A1 (en) | 2022-04-28 | 2023-11-01 | Evonik Operations GmbH | Multifunctional wax dispersant for subterranean chemical applications |
EP4269530A1 (en) | 2022-04-28 | 2023-11-01 | Evonik Operations GmbH | Multifunctional wax dispersant for subterranean chemical applications |
WO2024002738A1 (en) | 2022-06-28 | 2024-01-04 | Evonik Operations Gmbh | Composition comprising biosurfactant and persicomycin |
EP4361238A1 (en) | 2022-10-26 | 2024-05-01 | ChemTEK UG (haftungsbeschränkt) | Compositions comprising glycamines |
WO2024115213A1 (en) | 2022-11-30 | 2024-06-06 | Evonik Operations Gmbh | Detergent compartment pouch comprising biosurfactants |
EP4382090A1 (en) | 2022-12-08 | 2024-06-12 | Evonik Operations GmbH | Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof |
WO2024132679A1 (en) | 2022-12-21 | 2024-06-27 | Evonik Dr. Straetmans Gmbh | Compositions containing biosurfactants and desferrioxamines |
WO2025137065A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Cleansing wipe comprising hydrophobic polymer |
WO2025137028A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Cosmetic emulsion comprising hydrophobic polymer |
WO2025137014A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Mineral sunscreen and pigment dispersion comprising hydrophobic polymer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0123073B1 (en) * | 1993-12-28 | 1997-11-13 | 성재갑 | Cosmetic composition containing bio-surfactant |
US5756471A (en) * | 1994-06-13 | 1998-05-26 | Institut Francais Du Petrole | Use of a sophorolipid to provide free radical formation inhibiting activity or elastase inhibiting activity |
JP2003201209A (en) * | 2001-12-28 | 2003-07-18 | Nonogawa Shoji Kk | Skin care preparation |
-
2002
- 2002-10-14 KR KR1020020062439A patent/KR20040033376A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0123073B1 (en) * | 1993-12-28 | 1997-11-13 | 성재갑 | Cosmetic composition containing bio-surfactant |
US5756471A (en) * | 1994-06-13 | 1998-05-26 | Institut Francais Du Petrole | Use of a sophorolipid to provide free radical formation inhibiting activity or elastase inhibiting activity |
JP2003201209A (en) * | 2001-12-28 | 2003-07-18 | Nonogawa Shoji Kk | Skin care preparation |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563490B2 (en) | 2010-03-31 | 2013-10-22 | Conopco, Inc. | Mild to the skin, foaming detergent composition |
WO2011120776A1 (en) | 2010-03-31 | 2011-10-06 | Unilever Plc | Mild to the skin, foaming detergent composition |
DE102011090030A1 (en) | 2011-12-28 | 2013-07-04 | Evonik Industries Ag | Aqueous hair and skin cleansing compositions containing biosurfactants |
WO2013098066A2 (en) | 2011-12-28 | 2013-07-04 | Evonik Industries Ag | Aqueous hair and skin cleaning compositions comprising biotensides |
US9271908B2 (en) | 2011-12-28 | 2016-03-01 | Evonik Industries Ag | Aqueous hair and skin cleaning compositions comprising biotensides |
DE102013206314A1 (en) | 2013-04-10 | 2014-10-16 | Evonik Industries Ag | Cosmetic formulation containing copolymer as well as sulfosuccinate and / or biosurfactant |
EP3070155A1 (en) | 2015-03-18 | 2016-09-21 | Evonik Degussa GmbH | Composition comprising peptidase and biosurfactant |
WO2016146497A1 (en) | 2015-03-18 | 2016-09-22 | Evonik Degussa Gmbh | Composition containing peptidase and biosurfactant |
EP3907272A1 (en) | 2015-03-18 | 2021-11-10 | Evonik Operations GmbH | Composition comprising peptidase and biosurfactant |
US10988713B2 (en) | 2015-03-18 | 2021-04-27 | Evonik Operations Gmbh | Composition containing peptidase and biosurfactant |
US10718060B2 (en) | 2015-06-25 | 2020-07-21 | Basf Se | Additive for alkaline zinc plating |
WO2016207203A1 (en) | 2015-06-25 | 2016-12-29 | Basf Se | Additive for alkaline zinc plating |
EP3290020A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Mild preparations containing alkoxylated fatty acid amides |
EP3290501A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Detergent compositions containing alkoxylated fatty acid amides |
EP3998059A1 (en) | 2016-08-29 | 2022-05-18 | Perfect Ideas GmbH | Mild preparations as cleaning or care compositions for removing carbohydrates or stains |
EP3290500A1 (en) | 2016-08-29 | 2018-03-07 | Richli, Remo | Detergent composition and care composition containing polyoxyalkylene carboxylate |
WO2018101717A1 (en) * | 2016-11-29 | 2018-06-07 | 바이오인터체인지주식회사 | Composition containing sophorolipid as active ingredient for preventing hair loss or promoting hair growth |
US11464717B2 (en) | 2017-02-10 | 2022-10-11 | Evonik Operations Gmbh | Oral care composition containing at least one biosurfactant and fluoride |
WO2018145966A1 (en) | 2017-02-10 | 2018-08-16 | Evonik Degussa Gmbh | Oral care composition containing at least one biosurfactant and fluoride |
WO2018197623A1 (en) | 2017-04-27 | 2018-11-01 | Evonik Degussa Gmbh | Biodegradable cleaning composition |
US11746307B2 (en) | 2017-04-27 | 2023-09-05 | Evonik Operations Gmbh | Biodegradable cleaning composition |
US11591547B2 (en) | 2017-04-27 | 2023-02-28 | Evonik Operations Gmbh | Biodegradable cleaning composition |
CN110831571A (en) * | 2017-05-07 | 2020-02-21 | 轨迹Ip有限责任公司 | Cosmetic composition for skin health and method of use |
KR20190023016A (en) * | 2017-08-25 | 2019-03-07 | 주식회사 더가든오브내추럴솔루션 | Anti acne cosmetic composition and preparation method of the same comprising the mixed extract of Sopholiance S, Withania Somnifera Root, Coriandrum Sativum and Propolis |
KR20190033962A (en) * | 2017-09-22 | 2019-04-01 | 주식회사 유나이티드엑티브 | Fermented emulsifier using microorganism and preparation thereof |
WO2019214968A1 (en) | 2018-05-11 | 2019-11-14 | Basf Se | Detergent composition comprising rhamnolipids and/or mannosylerythritol lipids |
KR20190141904A (en) * | 2018-06-15 | 2019-12-26 | 한국생명공학연구원 | Method for high production of sophorolipid using Candida bombicola LA-200 strain having sophorolipid production activity |
WO2023161179A1 (en) | 2022-02-24 | 2023-08-31 | Evonik Operations Gmbh | New composition containing liposomes and biosurfactants |
EP4234671A1 (en) | 2022-02-24 | 2023-08-30 | Evonik Operations GmbH | Compositions containing biosurfactants and a lipase from stachybotrys chlorohalonata |
EP4269531A1 (en) | 2022-04-28 | 2023-11-01 | Evonik Operations GmbH | Multifunctional wax dispersant for subterranean chemical applications |
EP4269530A1 (en) | 2022-04-28 | 2023-11-01 | Evonik Operations GmbH | Multifunctional wax dispersant for subterranean chemical applications |
US11999901B2 (en) | 2022-04-28 | 2024-06-04 | Evonik Operations Gmbh | Multifunctional wax dispersant for subterranean chemical applications |
WO2024002738A1 (en) | 2022-06-28 | 2024-01-04 | Evonik Operations Gmbh | Composition comprising biosurfactant and persicomycin |
EP4361238A1 (en) | 2022-10-26 | 2024-05-01 | ChemTEK UG (haftungsbeschränkt) | Compositions comprising glycamines |
WO2024115213A1 (en) | 2022-11-30 | 2024-06-06 | Evonik Operations Gmbh | Detergent compartment pouch comprising biosurfactants |
EP4382090A1 (en) | 2022-12-08 | 2024-06-12 | Evonik Operations GmbH | Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof |
WO2024120910A1 (en) | 2022-12-08 | 2024-06-13 | Evonik Operations Gmbh | Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof |
WO2024132679A1 (en) | 2022-12-21 | 2024-06-27 | Evonik Dr. Straetmans Gmbh | Compositions containing biosurfactants and desferrioxamines |
WO2025137065A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Cleansing wipe comprising hydrophobic polymer |
WO2025137028A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Cosmetic emulsion comprising hydrophobic polymer |
WO2025137014A1 (en) | 2023-12-18 | 2025-06-26 | L'oreal | Mineral sunscreen and pigment dispersion comprising hydrophobic polymer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20040033376A (en) | Cosmetics composition comprising sophorolipids | |
US12233152B2 (en) | Yeast-based masks for improved skin, hair and scalp health | |
US11691937B2 (en) | Use of vanillin derivatives as preserving agents, preserving process, compounds and composition | |
JP2023061924A (en) | Cosmetic compositions for skin health and methods of using the same | |
JP4904811B2 (en) | External preparation for skin comprising a carbohydrate derivative of α, α-trehalose | |
KR100283793B1 (en) | Use of octoxyglycerin in a cosmetic and/or dermatological composition as active agent for the treatment of seborrhoea and/or acne | |
AU706143B2 (en) | Antiodor, antimicrobial and preservative compositions and methods of using same | |
JP2008069075A (en) | Skin external composition | |
DE69916695T2 (en) | Use of at least one hydroxystilbene as an agent for reducing the adhesion of microorganisms | |
KR20090038648A (en) | Cosmetic composition for acne skin containing cypress oil | |
CN118176005A (en) | Biosurfactant formulations for skin care and wound treatment | |
JP3327699B2 (en) | Antibacterial / preservative and cosmetics containing kujin extract | |
KR101274811B1 (en) | Potent anti-acne composition containing perilla frutescens and/or lygodium japonicum extract | |
JPH06157278A (en) | Skin external preparation for acne vulgaris | |
CA3083192A1 (en) | Propanediol monoacetate mononitrate | |
KR100570847B1 (en) | Acne skin composition | |
US20220193025A1 (en) | Use of dianhydrohexitol to eliminate the cosmetic effects of acne, dandruff and bad odors | |
JP2021185879A (en) | Yeast culture extract and skin preparation containing the same | |
EP0640581A1 (en) | Endermic nutrient material and cosmetic composition containing the same | |
KR102643628B1 (en) | A composition for improving milium comprising lactic acid bacteria | |
JP2004026657A (en) | Cosmetic for bleaching | |
JP2007161654A (en) | Antiseptic microbicide, cosmetic or medicine comprising the same antiseptic microbicide formulated therein and antiseptic microbicidal method | |
JP2025080757A (en) | Antibacterial composition for acne bacteria in keratin plugs | |
KR20070098116A (en) | External composition for the treatment of bacterial skin disease | |
KR20240040440A (en) | An antibacterial composition comprising chaenocephalus aceratus extract or trematomus bernacchii extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20021014 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041028 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20050127 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20041028 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |